Can a psychiatric‑mental‑health nurse practitioner (PMHNP) with prescriptive authority prescribe gabapentin for pruritus in a patient with chronic kidney disease who does not have gout?

Can a PMHNP Prescribe Gabapentin for Itch?

Yes, a psychiatric-mental health nurse practitioner (PMHNP) with prescriptive authority can legally prescribe gabapentin for pruritus in a patient with chronic kidney disease, as gabapentin is an appropriate evidence-based treatment option for uremic pruritus in CKD patients.

Scope of Practice Consideration

PMHNPs with prescriptive authority are licensed to prescribe medications within their scope of practice, which varies by state but generally includes medications for conditions they are competent to treat. While gabapentin is commonly used in psychiatric practice for various indications, prescribing for pruritus in CKD requires:

• Clinical competency in managing the condition
• Understanding of renal dosing adjustments
• Awareness of CKD-specific safety considerations

If the PMHNP lacks expertise in managing CKD-associated pruritus, referral to nephrology or dermatology would be more appropriate than prescribing outside their area of competence.

Evidence for Gabapentin in CKD-Associated Pruritus

Guideline Support

Gabapentin is recommended as a treatment option for uremic pruritus according to the British Association of Dermatologists 2018 guidelines 1. The guidelines specifically state:

• "Consider capsaicin cream, topical calcipotriol or oral gabapentin" for uremic pruritus (Strength of recommendation D; Level of evidence 3) 1
• Gabapentin has been shown effective in double-blind, placebo-controlled trials in hemodialysis patients with pruritus unresponsive to antihistamines 1

Critical Dosing Considerations in CKD

Renal dosing is absolutely essential - standard doses used in non-CKD populations are inappropriate and dangerous:

• CKD patients on hemodialysis: 100-300 mg post-dialysis, three times per week (NOT daily) 1
• These are dramatically lower doses than the 900-3600 mg/day used in non-ESRD populations 1
• A multicenter trial showed good response with just 100 mg post-dialysis three times weekly 1

Important Safety Warnings

Recent evidence reveals significant safety concerns, particularly in non-dialysis CKD patients:

• Gabapentin half-life extends from 5-7 hours to 52-132 hours in advanced CKD - a 10- to 20-fold increase 2
• Elevated dementia risk in CKD patients taking gabapentin (HR 7.39 in CKD vs. 1.09 in non-CKD patients), with risk persisting even at low doses (≤300 mg) 2
• High rates of adverse effects even at low doses in CKD patients: altered mental state (37.8 per 100 patient-years), falls (20.4), dizziness (19.3), somnolence (15.2), and fractures (9.3) 3
• Dose-response relationship for adverse effects observed at doses as low as 100 mg/day, particularly in pruritus patients 3

Critical Contraindication: Hepatic Pruritus

Do NOT use gabapentin for hepatic pruritus - the guidelines explicitly state: "In hepatic pruritus, do not use gabapentin" (Strength of recommendation D) 1. This is a critical distinction from uremic pruritus.

Practical Prescribing Algorithm

Step 1: Verify the Diagnosis

• Confirm uremic pruritus (CKD-associated), not hepatic or other causes
• Exclude gout as a confounding diagnosis (though gout presence doesn't contraindicate gabapentin for pruritus) 4

Step 2: Assess Renal Function

• Obtain current eGFR and creatinine clearance - this is non-negotiable 5
• Determine dialysis status (hemodialysis, peritoneal dialysis, or non-dialysis CKD)

Step 3: Dose Selection Based on Renal Function

For hemodialysis patients:

• Start with 100 mg post-dialysis, three times weekly 1
• Can increase to 300 mg post-dialysis if needed and tolerated 1
• Never dose on non-dialysis days in anuric patients

For non-dialysis CKD (eGFR <60):

• Exercise extreme caution - this population shows the highest dementia risk 2
• Consider alternative therapies first given safety concerns 3, 2
• If gabapentin is used, start at the lowest possible dose with close monitoring

Step 4: Monitoring Requirements

• Check within 2-4 weeks for adverse effects: drowsiness, altered mental state, dizziness, falls risk 1, 3
• Monitor for cognitive changes particularly in non-dialysis CKD stages 3b-4 2
• Assess fall risk - consider physical therapy referral if balance concerns emerge

Step 5: Consider Alternatives

Given the emerging safety data, consider these alternatives first 1:

• Topical therapies: menthol, capsaicin cream, calcipotriol 1
• Phototherapy: BB-UVB (Strength of recommendation A for uremic pruritus) 1
• Newer agents: difelikefalin (if available) 6
• Avoid long-term sedating antihistamines (dementia risk) 1

Common Pitfalls to Avoid

1. Using standard (non-renal) dosing - this is the most dangerous error given the 10-20 fold increase in half-life 2
2. Prescribing for hepatic pruritus - explicitly contraindicated 1
3. Failing to adjust for renal function - gabapentin is almost exclusively renally excreted 5
4. Overlooking fall risk in elderly CKD patients - particularly concerning given high fracture rates 3
5. Assuming dose adjustment eliminates risk - recent data suggest cognitive safety concerns persist even at low doses in CKD 2

Bottom Line for PMHNPs

While legally permissible, prescribing gabapentin for CKD-associated pruritus requires specialized knowledge of renal dosing and CKD-specific safety considerations. If you lack expertise in managing CKD complications, the most appropriate action is referral to nephrology or dermatology rather than prescribing independently. If you do prescribe, use the lowest effective renal-adjusted dose, monitor closely for cognitive and fall-related adverse effects, and strongly consider alternative therapies first given emerging safety data 3, 2.